Rafei-Shamsabadi, D.A., Lehr, S., Behrens, M. und Meiß, F. (2022) Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy [cd]. Freiburg: Universität. doi:10.3390/cancers14030540.
Chicago Manual of Style 17th edition (full note)Rafei-Shamsabadi, David Ali, Saskia Lehr, Max Behrens, und Frank Meiß. Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy. Cd. Freiburg: Universität, [2022?], Freiburg: Universität, [2022?]. https://doi.org/10.3390/cancers14030540.
American Psychological Association 7th editionRafei-Shamsabadi, D. A., Lehr, S., Behrens, M., & Meiß, F. (ca. 2022). Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy [Cd]. Universität. https://doi.org/10.3390/cancers14030540
Modern Language Association 9th editionRafei-Shamsabadi, D. A., S. Lehr, M. Behrens, und F. Meiß. Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy. cd, Universität, 2022, https://doi.org/10.3390/cancers14030540.
ISO-690 (author-date, Deutsch)RAFEI-SHAMSABADI, David Ali, Saskia LEHR, Max BEHRENS und Frank MEISS, 2022. Additive intralesional interleukin-2 improves progression-free survival in a distinct subgroup of melanoma patients with prior progression under immunotherapy. Freiburg: Universität